APOB and Hypercholesterolemia: Mipomersen, administered subcutaneously in three phase III trials conducted in patients with moderate to severe hypercholesterolemia, demonstrated its efficacy in reducing levels of apoB, LDL-C, triglycerides, and Lp (a) when compared with a placebo [85,86,87].